GlassScriptPhysician profile
Andre M Fabien
NPI 1689758229
$5,607.44
in general payments reported to CMS, 2019-2025
27 companies · $16.73 in 2025
The $16.73 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $752 · 2021: $1,259 · 2022: $1,122 · 2023: $829 · 2024: $925 · 2025: $16.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,126.69 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,060.09 | 2019-2024 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.14 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Genzyme Corporation | $251.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.74 | 2020-2024 | Dupixent |
| Vapotherm INC | $196.94 | 2019-2022 | |
| Amgen INC. | $193.80 | 2022-2024 | Tezspire |
| Mallinckrodt Hospital Products INC. | $174.48 | 2021-2023 | Acthar |
| Grifols USA, LLC | $151.77 | 2019-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $128.67 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $116.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $85.21 | 2019-2023 | |
| Genentech USA, INC. | $71.25 | 2019-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $69.82 | 2020-2022 | |
| Philips North America LLC | $47.29 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $28.77 | 2023 | Inspire |
| Harmony Biosciences LLC | $25.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.00 | 2021 | |
| Advanced Respiratory, INC | $21.09 | 2020 | |
| Nabriva Therapeutics, Plc | $20.61 | 2021 | |
| Shionogi INC | $20.42 | 2021 | |
| Pulmonx Corporation | $19.43 | 2021 | |
| Portola Pharmaceuticals, LLC | $19.08 | 2020 | |
| Shire North American Group INC | $18.77 | 2019 | |
| Inogen, INC. | $17.34 | 2022 | |
| Pfizer INC. | $14.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Fabien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.